A Big Data Approach to Predict NEOnatal Acute Kidney Injury in Newborns expoSed to nephroTOxic Drugs (NeoAKI STOP) (NeoAKISTOP)

May 5, 2023 updated by: Giacomo Cavallaro, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Predicting Acute Kidney Injury in Infants Exposed to Nephrotoxic Drugs: A Big Data Approach to Predict NEOnatal Acute Kidney Injury in Newborns expoSed to nephroTOxic Drugs. (NeoAKI STOP)

This observational retrospective study aims to learn about the incidence of acute kidney (AKI) injury in newborns in infants exposed to nephrotoxic drugs with a big data approach.

The main question it aims to answer are:

  • Develop a model that can predict the occurrence of AKI in infants admitted to the NICU;
  • Identify the drug or combination of drugs associated with an increased risk of AKI.

The group of infants exposed to drugs will be defined based on exposure for at least 1-day tone one or more therapies commonly used in the NICU. Once the AKI event has occurred, the observation of the trend of daily creatinine and diuresis values will be continued for the period covered by the study.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

  1. Rationale and background Acute Kidney Injury (AKI) is defined as the sudden impairment of kidney function that results in altered hydro electrolyte balance and renal waste product elimination.

    Extensive evidence shows that the onset of AKI in critically ill pediatric patients is associated with an increased risk of death and a longer length of hospitalization. Furthermore, in patients who survive an episode of AKI, there is an increased risk of developing long-term morbidity, particularly Chronic Kidney Disease (CKD).

    The neonatal kidney has numerous features on the pathophysiological level that predispose this population more to AKI than at other life ages.

    In addition to the peculiarities related to the development and physiology of the kidney, especially if preterm, infants admitted to the NICU are exposed to multiple risk factors that may contribute to the onset of AKI.

    A recent multicenter study conducted in neonatal intensive care units in Canada, Australia, India, and the United States reported an overall incidence of AKI of 29.9% and showed that the development of AKI is an independent risk factor for death and prolonged hospitalization. The incidence of AKI by gestational age also showed a typical U-shaped distribution, with the greater occurrence at the two extremes represented by infants with gestational ages >36 weeks (36.7%) and <29 weeks (47.9%), while the lowest value was recorded in the 29-36 weeks range.

    The risk of developing acute kidney injury is known to increase with the number of medications used (especially if > 3) and the duration of exposure, especially for the aminoglycoside antibiotic category. In addition, critically ill patients who developed AKI were generally more exposed to nephrotoxic drugs than those who did not develop AKI. In the NICU setting, it is estimated that 87% of VLBW infants are exposed to at least one nephrotoxic drug during their hospital stay, and about a quarter of these infants develop at least one episode of acute renal distress.

    The diagnosis of AKI is based on increased serum creatinine (SCr) or decreased urinary output.

    To date, the definition of acute kidney injury is based on the former Kidney Disease Improving Global Outcomes (KIDGO) criteria modified for newborns.

    However, in light of the premises made, it can be understood how creatinine monitoring allows only passive observation of the phenomenon, noting the rise in creatinine values when renal insult has already occurred by then. This allows only retrospective changes in some aspects of the infant's management, such as optimizing fluid intake, suspending the administration of nephrotoxic drugs, and correcting any electrolyte imbalances, but without being able to prevent the onset of AKI. Ideally, the investigators should be able to understand and predict how different risk factors contribute to the beginning of renal damage in a given patient, thus allowing individualized management.

    Given the complexity of patients admitted to the NICU and the number of variables in the field, the problem lends itself well to analysis through AI and general statistical inference methods. Such methods have previously been used successfully for studies on adult patients but, to our knowledge, never on newborn patients.

    The investigators hope to apply these models in a prospective cohort study to validate their use and develop a real-time monitoring system of the kidney well-being of our nephrotoxic drug-exposed infants that can guide the clinician in patient management. Indeed, systematic surveillance of at-risk patients can significantly reduce the onset of kidney damage and limit both short-term and long-term consequences, thereby improving neonatal outcomes.

  2. Research question and objectives 2.1 Primary objectives

    • Develop a model that can predict the occurrence of AKI in infants admitted to the NICU;
    • Identify the drug or combination associated with an increased risk of AKI. 2.2 Secondary objectives
    • Identify subgroups of patients at increased risk of AKI;
    • Identify time windows at increased risk of AKI during NICU admission.

  3. Methods 3.1 Study design Single-center retrospective observational cohort study at the UOC of Neonatology and Neonatal Intensive Care Unit of Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.

    3.1.1 Primary endpoints

    • Development of AKI defined according to modified KIDGO criteria for the newborn based on increased serum creatinine values or reduced mean hourly diuresis during NICU admission.

    3.1.2 Secondary endpoints

    • Number of AKI cases in risk subcategories: very low birth weight (birth weight < 1500 g), extremely low birth weight (birth weight < 1000 g), cardiopathic, with surgical pathology, sepsis, asphyxia;
    • Number of AKI cases in the first week of hospitalization compared with other periods.

  4. Setting A population of infants admitted to the NICU of the Foundation will be retrospectively considered.

    4.1 Study population The study population will consist of patients born between January 2010 and December 2022.

  5. Inclusion criteria

    • Patients who meet all of the following criteria will be included in the study:

    • born between 01/01/2010 and 31/12/2022;
    • admitted within 24 hours of birth in the NICU (both inborn and outborn);
    • availability of at least two serum creatinine values or a daily hourly diuresis assessment in the first 30 days of life.

  6. Exclusion Criteria

    Patients who meet even one of the following criteria will be excluded:

    • pre- or postnatal diagnosis of severe urologic and/or nephrologic pathology on a malformative and/or genetic basis;
    • finding of serum creatinine > 2 mg/dl in the first 24 hours of life;
    • genetic conditions that may impact patient survival or renal function;
    • length of stay in the NICU less than 48 hours (death or transfer to another department);
    • infants undergoing ECMO.

  7. Variables Clinical and instrumental data regarding each patient's medical history will be acquired for the NICU admission by the first month of life.

    Definition of AKI All available serum creatinine values for each patient during the NICU admission will be recorded, considering that determinations made within the first 48 hours of the infant's life are affected by maternal creatinine values.

    The presence of AKI will be determined according to the modified KIDGO criteria for the newborn, as reported in previous work in the neonatal setting.

    Exposure to drugs. The group of infants exposed to drugs will be defined based on exposure for at least 1-day tone one or more therapies commonly used in the NICU. Special attention will be given to exposure to antibiotics, antivirals, antifungals, diuretics, anti-inflammatories, inotropes, and vasopressors. In addition to the active ingredient, other significant data such as prescribed dose, administration route, treatment duration, and temporal relationship between treatment and diagnosis of AKI will also be considered. Once the AKI event has occurred, the observation of the trend of daily creatinine and diuresis values will be continued for the period covered by the study.

  8. Source documents Data will be collected from each newborn's Neocare electronic medical record (GPI SpA).
  9. Sample size Approximately 600 newborns are admitted to the neonatal intensive care unit each year. The incidence of renal damage in the critically ill newborn population is reported in the literature to be approximately 30%. In light of these considerations, over the decade of our observation, the estimated number of infants admitted to the NICU is about 6000 patients. Assuming a 30% drop-out related to exclusion criteria (about 1800 subjects), the investigators expect to be able to include approximately 4200 subjects in the study, among whom the investigators should find about 1200 cases of acute renal damage.
  10. Data management Data will be collected anonymously by assigning a code to each patient. They will then be organized and stored on data storage systems with secure access.
  11. Data Analysis Data will be analyzed using statistical inference approaches peculiar to Data Science and Artificial Intelligence (AI), such as Decision Trees, Logistic Regression, and Machine Learning (ML). The data themselves will suggest the choice of methods used.
  12. Primary endpoint: analysis Identifying patterns or items in the administration of so-called off-label drugs in the neonatal patient (premature or not) and the development of renal syndromes related to the administration of the drug itself. Once one or more correlation factors have been identified, they could be entered within the Electronic Medical Record system (and in particular within the Clinical Decision Support System) in order to be able to alert the treating clinical staff of any clinical risk associated with the administration.
  13. Secondary endpoint: analysis Development of a computational Early Warning model for AKI that ensures the interpretability of the prediction.

Study Type

Observational

Enrollment (Anticipated)

4200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Italy
    • MI
      • Milan, MI, Italy, 20129
        • Neonatal Intensive Care Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

patients admitted to NICU and born between January 2010 and December 2022

Description

Inclusion Criteria:

  • born between 01/01/2010 and 31/12/2022;
  • admitted within 24 hours of birth in the NICU (both inborn and outborn);
  • availability of at least two serum creatinine values or a daily hourly diuresis assessment in the first 30 days of life.

Exclusion Criteria:

  • pre- or postnatal diagnosis of severe urologic and/or nephrologic pathology on a malformative and/or genetic basis;
  • finding of serum creatinine > 2 mg/dl in the first 24 hours of life;
  • genetic conditions that may impact patient survival or renal function;
  • length of stay in the NICU less than 48 hours (death or transfer to another department);
  • infants undergoing ECMO.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Develop a model that can predict the occurrence of AKI in infants admitted to the NICU;
Time Frame: From the date of randomization until the date of the first documented progression of AKI and up to 4 weeks

All available serum creatinine values for each patient during the NICU admission will be recorded, considering that determinations made within the first 48 hours of the infant's life are affected by maternal creatinine values.

The presence of AKI will be determined according to the modified KIDGO criteria for the newborn, as reported in previous work in the neonatal setting (Jetton JG, 2017; Jetton JG and Askenazi DJ, 2012; Stoops C, 2016; Askenazi DJ, Patil NR, et al., 2015; Sarkar S, 2014).
From the date of randomization until the date of the first documented progression of AKI and up to 4 weeks
Identify the drug or combination of drugs associated with an increased risk of AKI
Time Frame: From the date of randomization until the date of the first documented progression of AKI and up to 4 weeks
The group of infants exposed to drugs will be defined based on exposure for at least 1-day tone one or more therapies commonly used in the NICU. Special attention will be given to exposure to antibiotics, antivirals, antifungals, diuretics, anti-inflammatories, inotropes, and vasopressors. In addition to the active ingredient, other significant data such as prescribed dose, administration route, treatment duration, and temporal relationship between treatment and diagnosis of AKI will also be considered.
From the date of randomization until the date of the first documented progression of AKI and up to 4 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Identify subgroups of patients at increased risk of AKI
Time Frame: From the date of randomization until the date of the first documented progression of AKI and up to 4 weeks
Number of AKI cases in risk subcategories: very low birth weight (birth weight < 1500 g), extremely low birth weight (birth weight < 1000 g), cardiopathic, with surgical pathology, sepsis, asphyxia
From the date of randomization until the date of the first documented progression of AKI and up to 4 weeks
Identify time windows at increased risk of AKI during NICU admission.
Time Frame: From the date of randomization until the date of the first documented progression of AKI and up to 4 weeks
Number of AKI cases in the first week of hospitalization compared with other periods
From the date of randomization until the date of the first documented progression of AKI and up to 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Investigators

  • Study Director: Giacomo Cavallaro, MD, PhD, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
  • Principal Investigator: Ilaria Amodeo, MD, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

August 1, 2023

Primary Completion (Anticipated)

September 30, 2023

Study Completion (Anticipated)

December 31, 2024

Study Registration Dates

First Submitted

April 9, 2023

First Submitted That Met QC Criteria

May 5, 2023

First Posted (Actual)

May 9, 2023

Study Record Updates

Last Update Posted (Actual)

May 9, 2023

Last Update Submitted That Met QC Criteria

May 5, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NeoAKI STOP

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Premature Birth

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe